TORONTO, July 15, 2021 /CNW/ - SQI Diagnostics Inc.
(TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics
company that develops and commercializes proprietary technologies
and products for advanced microarray diagnostics ("SQI") and AZOVA
Inc., creator of the world's most comprehensive digital health
network for COVID-19 testing and vaccination management, today
announced the signing of an agreement that subject to an approval
by the Food & Drug Administration (FDA), will allow AZOVA to
sell and distribute SQI's COVID-19 HOME Antibody Test to its
customer base of airlines, wholesale clubs, retail pharmacies,
grocery chains, US state and international governments, school
districts and universities, and consumers where the test is
authorized for distribution through AZOVA's state-of-the-art online
digital health platform.
SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's
COVID-19 HOME Antibody Test
Once an application is submitted and Emergency Use Authorization
(EUA) from the FDA is granted, SQI's COVID-19 HOME Antibody Test
and Collection Kit is slated to be the most comprehensive consumer
test for antibodies to SARS-CoV-2, the virus which causes COVID-19,
as well as antibodies generated by the three major COVID-19
vaccines made by Pfizer, Moderna and Johnson & Johnson. SQI's
data show that the test is >99% accurate and will be the first
test of its kind for the consumer market. The test is designed to
detect all three immune responses (IgG, IgA, and IgM) from both
protein regions of the SARS-CoV-2 virus; the nucleocapsid and spike
regions.
Consumers, employees and travelers will be able to purchase a
test through AZOVA or from any of its retail partners. A collection
kit will be shipped to the consumer where they will take a small
blood sample via the supplies provided. That sample is then shipped
to one of SQI's partnering CLIA laboratories where the test will be
performed, and results will be sent back to the consumer through
AZOVA 12-48 hours after the lab receives the specimen.
AZOVA is changing the way consumers access healthcare. Through
AZOVA's globally connected digital health system, consumers can
access a wide range of healthcare services including telehealth,
behavioral health, vaccinations, medication management and
laboratory testing services. AZOVA has also pioneered the COVID
Credentials™ Health Pass, an electronic vaccination record source
verification service. This service provides an electronic and
globally shareable vaccination record for anyone to use for back to
work, back to school, and back to travel.
"This is an exciting day for SQI," said Clive Beddoe, interim CEO and Chairman of the
Board of Directors at SQI. "AZOVA is the ideal partner to
distribute our revolutionary COVID-19 HOME Antibody Test. They are
perfectly poised to provide this valuable new test to anyone who
may need it, helping to bring about health and normalcy to a world
that has been shaken to its core by the pandemic."
"SQI's COVID-19 antibody test is the perfect complement to our
comprehensive COVID testing and vaccination management portfolio.
Not only do we all want to know our COVID antibody status before or
after infection, but we also want to know if we've formed
antibodies after vaccination and how many of those antibodies we
have and for how long they persist" said Cheryl Lee Eberting, M.D., CEO & Founder of
AZOVA. "This test can be used to track antibody status over time
for an individual or for an entire population. With this kind of
information, we can answer some of the most important questions
about COVID and our immune response to it."
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that
is leading the way in healthcare utilizing state-of-the-art
technology to rapidly diagnose, triage and provide medical insights
to patients. We strive to improve people's lives and assist their
healthcare providers by providing quality clinical health
information backed by years of research and clinical data. For more
information, please visit www.sqidiagnostics.com.
About AZOVA
AZOVA is a globally connected Digital Health System providing
telehealth and digital health services through globally connected
provider, pharmacy, and laboratory networks. AZOVA provides
innovative COVID testing and vaccination solutions for employers,
schools, government entities, airlines, the travel industry, and
the consumer. AZOVA has created the world's first truly connected
global laboratory network to enable travelers to access COVID
testing anywhere in the world. For more information, visit
azova.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sqi-diagnostics-and-azova-sign-distribution-agreement-to-sell-sqis-covid-19-home-antibody-test-301335346.html
SOURCE SQI Diagnostics Inc.